Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Mcl-1 gene promoter insertions do not correlate with disease outcome, stage or VH gene mutation status in chronic lymphocytic leukaemia

Leukemia volume 19, pages 871–873 (2005)Cite this article

TO THE EDITOR

Chronic lymphocytic leukaemia (CLL) is a clinically heterogeneous disease with many patients surviving for years with little or no treatment, while others have a more aggressive disease. In clinical practice, two staging systems are currently widely used (Rai and Binet), but except for these, few good prognostic markers exist that can predict outcome at an early stage of the disease. During recent years, however, the immunoglobulin VH gene mutation status has emerged as an important prognostic factor, since cases displaying mutated VH genes have superior prognosis to unmutated cases.1, 2

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854.

    CAS  PubMed  Google Scholar 

  2. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847.

    CAS  PubMed  Google Scholar 

  3. Saxena A, Viswanathan S, Moshynska O, Tandon P, Sankaran K, Sheridan DP . Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol 2004; 75: 22–33.

    Article  CAS  Google Scholar 

  4. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379–3389.

    CAS  PubMed  Google Scholar 

  5. Johnston JB, Paul JT, Neufeld NJ, Haney N, Kropp DM, Hu X et al. Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia. Leukemia Lymphoma 2004; 45: 2017–2027.

    Article  CAS  Google Scholar 

  6. Moshynska O, Sankaran K, Pahwa P, Saxena A . Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. J Natl Cancer Inst 2004; 96: 673–682.

    Article  CAS  Google Scholar 

  7. Tobin G, Thunberg U, Johnson A, Thorn I, Soderberg O, Hultdin M et al. Somatically mutated Ig V(H)3–21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002; 99: 2262–2264.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are grateful to Drs Lars Klareskog and Leonid Padyukov and to the EIRA group for help with the collection of the normal control material. This study was supported by grants from the Swedish Cancer Society, Lion's Cancer Research Foundation, Uppsala and the research foundation of the Department of Oncology at Uppsala University.

Author information

Author notes

  1. G Tobin and Å Skogsberg: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden

    G Tobin, Å Skogsberg, C Sundström, K Nilsson & R Rosenquist

  2. Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden

    U Thunberg & A Laurell

  3. Department of Medical Sciences, Uppsala University Hospital, Umeå University, Sweden

    A Åleskog

  4. Department of Medicine at Huddinge University Hospital, Umeå University, Sweden

    M Merup

  5. Department of Medical Biosciences, Pathology, Umeå University, Sweden

    G Roos

Authors
  1. G Tobin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Å Skogsberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U Thunberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Laurell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Åleskog
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Merup
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Sundström
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Roos
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Nilsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R Rosenquist
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Tobin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tobin, G., Skogsberg, Å., Thunberg, U. et al. Mcl-1 gene promoter insertions do not correlate with disease outcome, stage or VH gene mutation status in chronic lymphocytic leukaemia. Leukemia 19, 871–873 (2005). https://doi.org/10.1038/sj.leu.2403715

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403715

This article is cited by

Search

Advanced search

Quick links